EviCure
EviCure develops extracellular vesicle (EV)–based therapeutics designed to produce targeted anti-tumor effects across a range of solid cancers. The company combines EV engineering with AI-driven analytics and advanced human cancer disease models to identify effective stem cell subpopulations and EV payloads. Its platform enables EVs to act both as endogenous anti-cancer agents and as delivery vehicles for RNA therapies, peptides, and small molecules. EviCure also uses AI algorithms and biological sensors to scale up EV manufacturing with consistent potency and reproducibility. The company operates as a biotechnology therapeutics developer focused on clinical-stage treatments for lung and other solid tumors.
EviCure
EviCure develops extracellular vesicle (EV)–based therapeutics designed to produce targeted anti-tumor effects across a range of solid cancers. The company combines EV engineering with AI-driven analytics and advanced human cancer disease models to identify effective stem cell subpopulations and EV payloads. Its platform enables EVs to act both as endogenous anti-cancer agents and as delivery vehicles for RNA therapies, peptides, and small molecules. EviCure also uses AI algorithms and biological sensors to scale up EV manufacturing with consistent potency and reproducibility. The company operates as a biotechnology therapeutics developer focused on clinical-stage treatments for lung and other solid tumors.